Full Press Release Details
LONDON--(BUSINESS WIRE)--$SLN#SenseofSilence--Silence Therapeutics plc, (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced a conference call and webcast to discuss topline results from the Phase 2 SANRECO trial of divesiran in polycythemia vera (PV) scheduled for tomorrow, Monday, August 10, 2026 at 8:00 a.m. EDT.
Investor Webcast & Conference Call Information
Conference call link:https://register-conf.media-server.com/register/BI4a60039edc0640388f2ba0a6aab560e2
Webcast link:https://edge.media-server.com/mmc/p/q6mmpxd5
A replay of the webcast will be available on the Investors section of the Silence website atwww.silence-therapeutics.com/events.
About Silence TherapeuticsSilence Therapeutics is a global clinical-stage biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines created with proprietary siRNA (short interfering RNA) technology. Silence leverages its mRNAi GOLD™ platform to create innovative siRNA therapies designed to precisely target and silence genes that cause disease. The Company is advancing a growing pipeline of siRNA product candidates targeting areas of high unmet need across rare and common diseases where treatments are limited or inadequate. For more information, please visithttps://www.silence-therapeutics.com/.